-
21.
公开(公告)号:CA2315117C
公开(公告)日:2011-03-15
申请号:CA2315117
申请日:1998-12-18
Applicant: ABBOTT LAB
Inventor: HOLLADAY MARK W , ABREO MELWYN A , GUNN DAVID E , LIN NAN-HORNG , GARVEY DAVID S , RYTHER KEITH , LEBOLD SUZANNE A , ELLIOTT RICHARD L , HE YUN , WASICAK JAMES T , BAI HAO , DART MICHAEL J , EHRLICH PAUL P , LI YIHONG , KINCAID JOHN F , SCHKERYANTZ JEFFREY M , LYNCH JOHN K
IPC: C07D401/12 , A61K31/40 , A61K31/425 , A61K31/427 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/50 , A61K31/501 , A61K31/505 , A61K31/506 , A61P25/00 , A61P25/22 , A61P25/28 , A61P25/30 , A61P43/00 , C07D403/12 , C07D417/12 , C07D455/02 , C07D487/04
Abstract: Novel compounds having formulas (I), (II) or (III) or pharmaceutically-acceptable salts or prodrugs thereof, which are useful for controlling synaptic transmission; to therapeutically-effective pharmaceutical compositions of these compounds; and to the use of said compositions to controlling synaptic transmission in human or veterinary patients.
-
公开(公告)号:BG64196B1
公开(公告)日:2004-04-30
申请号:BG10355699
申请日:1999-07-06
Applicant: ABBOTT LAB
Inventor: HOLLADAY MARK W , ARNERIC STEPHEN P , BAI HAO , DART MICHAEL J , LIN NAN-HORNG , LYNCH JOHN K , OR YAT S , RYTHER KEITH B , SULLIVAN JAMES P , WASICAK JAMES T , EHRLICH PAUL P
IPC: A61P25/04 , A61K31/4427 , A61K31/443 , A61K31/4439 , A61K31/485 , A61P25/28 , A61P29/00 , C07D205/04 , C07D401/12 , C07D401/14 , C07D405/14 , A61K31/44
Abstract: The invention relates to a method for pain control in mammals, including humans where selected compounds are applied with the formula or their pharmaceutically acceptable salts, the meaning of the substituents being listed in the description. The invention also relates to selected (R) and (S) compounds with formula I which can be used as analgetics, as means for the prevention of dying of neuron cells and as antiphlogistic preparations. 39 claims, 6 figures
-
公开(公告)号:AT227717T
公开(公告)日:2002-11-15
申请号:AT97952392
申请日:1997-12-10
Applicant: ABBOTT LAB
Inventor: HOLLADAY MARK W , ARNERIC STEPHEN P , BAI HAO , DART MICHAEL J , LIN NAN-HORNG , LYNCH JOHN K , OR YAT SUN , RYTHER KEITH B , SULLIVAN JAMES P , WASICAK JAMES T , EHRLICH PAUL P
IPC: A61P25/04 , A61K31/4427 , A61K31/443 , A61K31/4439 , A61K31/485 , A61P25/28 , A61P29/00 , C07D205/04 , C07D401/12 , C07D401/14 , C07D405/14 , A61K31/44
Abstract: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula (I) which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.
-
公开(公告)号:GR3036075T3
公开(公告)日:2001-09-28
申请号:GR20010400919
申请日:2001-06-19
Applicant: ABBOTT LAB
Inventor: ELLIOTT RICHARD L , RYTHER KEITH B , HOLLADAY MARK W , WASICAK JAMES T , DAANEN JEROME F
IPC: A61K31/00 , A61K31/435 , A61K31/4353 , A61K31/4355 , A61P9/00 , A61P25/00 , A61P25/30 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/044 , C07D491/048 , C07D495/04 , C07D519/00
Abstract: Novel heterocyclic ether compounds having the formula: wherein A, m, R, X, Y1, Y2 and Y3 are specifically defined, which are useful in selectively controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions thereof; and use of said compositions to selectively control synaptic transmission in mammals.
-
公开(公告)号:DK0842178T3
公开(公告)日:2001-08-06
申请号:DK96926133
申请日:1996-07-25
Applicant: ABBOTT LAB
Inventor: ELLIOTT RICHARD L , RYTHER KEITH B , HOLLADAY MARK W , WASICAK JAMES T , DAANEN JEROME F
IPC: A61K31/00 , A61K31/435 , A61K31/4353 , A61K31/4355 , A61P9/00 , A61P25/00 , A61P25/30 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/044 , C07D491/048 , C07D495/04 , C07D519/00
Abstract: Novel heterocyclic ether compounds having the formula: wherein A, m, R, X, Y1, Y2 and Y3 are specifically defined, which are useful in selectively controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions thereof; and use of said compositions to selectively control synaptic transmission in mammals.
-
公开(公告)号:ES2156998T3
公开(公告)日:2001-08-01
申请号:ES96926133
申请日:1996-07-25
Applicant: ABBOTT LAB
Inventor: ELLIOTT RICHARD L , RYTHER KEITH B , HOLLADAY MARK W , WASICAK JAMES T , DAANEN JEROME F
IPC: A61K31/00 , A61K31/435 , A61K31/4353 , A61K31/4355 , A61P9/00 , A61P25/00 , A61P25/30 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/044 , C07D491/048 , C07D495/04 , C07D519/00
Abstract: Novel heterocyclic ether compounds having the formula: wherein A, m, R, X, Y1, Y2 and Y3 are specifically defined, which are useful in selectively controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions thereof; and use of said compositions to selectively control synaptic transmission in mammals.
-
27.
公开(公告)号:NZ335810A
公开(公告)日:2001-03-30
申请号:NZ33581097
申请日:1997-12-10
Applicant: ABBOTT LAB
Inventor: HOLLADAY MARK W , ARNERIC STEPHEN P , BAI HAO , DART MICHAEL J , LIN NAN-HORNG , LYNCH JOHN K , OR YAT SUN , RYTHER KEITH B , SULLIVAN JAMES P , WASICAK JAMES T , ERHLICH PAUL P
IPC: A61P25/04 , A61K31/4427 , A61K31/443 , A61K31/4439 , A61K31/485 , A61P25/28 , A61P29/00 , C07D205/04 , C07D401/12 , C07D401/14 , C07D405/14
Abstract: An 3-(2-azetidinyl-methoxy)-pyridine derivative or a pharmaceutically acceptable salt thereof has the compound of formula I wherein: Z, Y, X and the 2-azetidine stereochemistry are, respectively, selected from: a) H, H, Me (R); b) H, H, CN (S); c) H, H, Cl (S); d) H, H, Cl (R); e) H, H, Br (R); f) H, H, F (S); g) H, H, F (R); h) H, H, CHF2 (S); i) H, H, OMe (R); j) H, Me, Cl (S); k) H, Me, Cl (R); l) H, Et, F (S); m) H, ethenyl, Cl (S); n) H, ethenyl, Cl (R); o) H, ethenyl, F (S); p) H, ethenyl, F (R); q) H, ethynyl, Cl (S); r) H, ethynyl, Cl (R); s) H, Cl, Cl (S); t) H, Cl, Cl (R); u) H, Cl, F (S); v) H, Br, Me (S); w) H, Br, Me (R); x) H, Br, Cl (S); y) H, Br, Cl (R); z) H, Br, F (S); aa) H, Br, F (R); bb) H, n-Pr, H (S); cc) H, ethenyl, H (S); dd) H, ethenyl, H (R); ee) H, Cl, H (R); ff) H, F, H (S); gg) H, NO2, H (S); hh) H, OEt, H (S); ii) Cl, H, H (S); jj) Cl, H, H (R); kk) F, H, H (S); ll) F, H, F (S); mm) F, H, Me (S) or nn) F, H, Me (R) and R is H or a prodrug such as methyl, ethyl, isopropyl, n-propyl, isobutyl, t-butyl, t-pentyl, n-pentyl, n-butyl, cyclohexylmethyl, 3-methyl-1-butyn-3 -yl, optionally N-protected-Ala, optionally N-protected-Phe, phthaloyl methyl ester, 4-diethylaminobenzoyl, 2-hydroxymethylbenzoyl, acetyl, t-butyloxycarbonyl, ethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, 4-methoxyphenoxycarbonyl, 4-carbomethoxyphenoxycarbonyl, 4-methylphenoxycarbonyl, 4-fluorophenoxycarbonyl, 4-chlorophenoxycarbonyl, 2,6-dimethylphenoxycarbonyl, 1 -acetoxy-1-methyl-ethoxycarbonyl, benzyloxycarbonyl, pyrrolidin-1-ylcarbonyl, N-succinimidylmethyl or N-phthalimidylmethyl or a group of formula 1, 2 (where R' is H or Me), 3, 4 or 5 (where two azetidines are attached). A pharmaceutical composition thereof is useful in controlling pain in mammals. An intermediate compound of formula II is disclosed wherein: L is an anionic leaving group which may be displaced by a nucleophile and P is a nitrogen protecting group.
-
公开(公告)号:BR9714677A
公开(公告)日:2000-10-03
申请号:BR9714677
申请日:1997-12-10
Applicant: ABBOTT LAB
Inventor: HOLLADAY MARK W , ARNERIC STEPHEN P , BAI HAO , DART MICHAEL J , LIN NAN-HORNG , LYNCH JOHN K , OR YAT SUN , RYTHER KEITH B , SULLIVAN JAMES P , WASICAK JAMES T , EHRLICH PAUL P
IPC: A61P25/04 , A61K31/4427 , A61K31/443 , A61K31/4439 , A61K31/485 , A61P25/28 , A61P29/00 , C07D205/04 , C07D401/12 , C07D401/14 , C07D405/14 , A61K31/44
Abstract: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula (I) which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.
-
公开(公告)号:CO4920251A1
公开(公告)日:2000-05-29
申请号:CO98008325
申请日:1998-02-17
Applicant: ABBOTT LAB
Inventor: WASICAK JAMES T , GARVEY DAVID S , HOLLADAY MARK W , HORNG LIN NAN , RYTHER KEITH B
IPC: A61P25/04 , A61K31/40 , A61K31/422 , A61K31/4439 , A61K31/4725 , A61P25/00 , A61P43/00 , C07D487/04
Abstract: Un compuesto que tiene la fórmula o una sal ó precursor de droga farmacéuticamente aceptable de éste, en donde el grupo designado como A se selecciona de un grupo conformado por: (a) en donde R1 es un alquil C1 -C3 , tal como se define más adelante, -CH2 -aril, aril- CH2 -sustituido, o aril-CH2 -CH2 -sustituido, en donde aril y aril sustituido corresponden a lo definido más adelante, (b) en donde R1 corresponde a lo previamente definido, y R2 es H ó alquil C1 -C3 ; (c)en donde R3 se encuentra sustituido en la posición 2, 4, ó 6 y se selecciona de un grupo conformado por H, alquil C1 -C3 , Br, Cl, o F, y R4 se encuentra sustituido en las posiciones restantes no ocupadas por R3 , y se selecciona independientemente de un grupo conformado por H, - 2 -alquil C1 -C3 , Br, Cl, F ó alquil C1 -C3 -O-; y en caso de que el compuesto se encuentre sustituido en la posición 5-, R4 puede adicionalmente seleccionarse de un grupo conformado por (1) O-R6 , en donde R6 se selecciona de un grupo conformado por (a) hidrógeno,(b) alquil de uno a seis átomos de carbono,(c) alquenil de uno a seis átomos de carbono(d) alquinil de uno a seis átomos de carbono(e) haloalquil de uno a seis átomos de carbono,(f) hidroxialquil de dos a seis átomos de carbono,(h) amina, (i) alquilamino de uno a seis átomos de carbono(j) dialaquilamino en el cual los dos grupos alquil son independientemente de uno a seis átomos de carbono,(k) fenil,(l) naftil,(m) bifenil,(n) furil,(o) tienil,(p) piridinil,(q) pirazinil,(r) piridazinil,(s) pirimidinil,(t) pirrolil,(u) pirazolil,(v) imidazolil,(w) indolil,(x) tiazolil,(i) oxazolil,(z) isoxazolil,(aa) tiadiazolil,(bb) oxadiazolil,(cc) quinolinil,(dd) isoquinolinil, (ee) aril-alquil C1 -C6 ,(ff) heteroaril-alquil C1 -C6 , y(gg) cualquiera de los grupos (1) hasta (ff) de R6 anteriores, sustituidos con uno o dos sustituyentes independientemente seleccionados de un grupo conformado por alquil de uno a seis átomos de carbono, haloalquil de uno a seis átomos de carbono, alcoxi de uno a seis átomos de carbono, alcoxialquil con el cual las porciones alcoxi y alquil son independientemente de uno a seis átomos de carbono,alcoxialcoxi en el cual las porciones alcoxi son independientemente de uno a seis átomos de carbono, halógeno, ciano, hidroxi, amino, alquilamino de uno a seis átomos de carbono, carboxil, y alcoxicarbonil de dos a seis átomos de carbono;(2) -S-R6 , en donde R6 corresponde a lo previamente definido; (3) -N(R6 )(R7 ), en donde R6 corresponde a lo previamente definido y R7 se selecciona entre H ó alquil de uno a seis átomos de carbono;(4) LR8 , en dondo L está ausente, ó se selecciona de un grupo conformado por:(a) -(CH2 )p , en donde p va de 1 - 6;(b) -(CH=CH)q -, en donde q es uno o dos;(c) -C(O)-;(d) -OC(O)-;(e) -N(R7 )-C(O)-, en donde R7 corresponde a lo previamente definido; (f) -CH2 -CH2 -C(O);(g) -CH2 -O-C(O)-; -CH2 -NH-C(O)-; ó (h) -CºC-, yen donde R8 se selecciona de un grupo conformado por:(a) hidrógeno,(b) alquil de uno a seis átomos de carbono,(c) alquenil de uno a seis átomos de carbono(d) alquinil de uno a seis átomos de carbono(e) haloalquil de uno a seis átomos de carbono,(f) hidroxialquil de uno a seis átomos de carbono,(g) alcoxi de uno a seis átomos de carbono,(h) amino,(i) alquilamino de uno a seis átomos de carbono,(j) dialquilamino en el cual los dos grupos alquil son independientemente de uno a seis átomos de carbono,(k) fenil,(l) naftil,(m) bifenil,(n) furil,(o) tienil,(p) piridinil,(q) pirazinil,(r) piridazinil,(s) pirimidinil,(t) pirrolil(u) pirazolil,(v) imidazolil,(w) indolil,(x) tiazolil,(i) oxazolil,(z) isoxazolil,(aa) tiadiazolil,(bb) oxadiazolil,(cc) quinolinil,(dd) isoquinolinil, y(ee) cualquiera de los grupos (l) hasta (dd) de R6 anteriores, sustituidos con uno o dos sustituyentes independientemente seleccionados de un grupo conformado por alquil de uno a seis átomos de carbono, haloalquil de uno a seis átomos de carbono, alcoxi de uno a seis átomos de carbono, alcoxialquil en el cual las porciones alcoxi y alquil son independientemente de uno a seis átomos de carbono, alcoxialcoxil en el cual las porciones alcoxi son independientemente de uno a seis átomos de carbono, halógeno, ciano, hidroxi amino, alquilamino de uno a seis átomos de carbono, carboxil, y alcoxicarbonil de dos a seis átomos de carbono;con la condición de que en los grupo del tipo AND#8209;OAND#8209;R6 , AND#8209;SAND#8209;R6 , AND#8209;N(R6 )(R7 ) y LAND#8209;R8 , ninguno de las posibilidades de R6 , AND#8209;N(R6 )(R7 ) ó LAND#8209;R8 pueden contener un átomo de nitrógeno que se encuentre en conjugación con un doble ó un triple enlace.(d) , en donde R3 corresponde a lo previamente definido;(e) , en donde R3 corresponde a lo previamente definido;(f) , en donde R3 corresponde a lo previamente definido;(g) , en donde R5 es H, alquil C1 AND#8209;C3 , CL o F
-
公开(公告)号:SK75999A3
公开(公告)日:2000-05-16
申请号:SK75999
申请日:1997-12-10
Applicant: ABBOTT LAB
Inventor: HOLLADAY MARK W , ARNERIC STEPHEN P , BAI HAO , DART MICHAEL J , LIN NAN-HORNG , LYNCH JOHN K , OR YAT SUN , RYTHER KEITH B , SULLIVAN JAMES P , WASICAK JAMES T , EHRLICH PAUL P
IPC: A61P25/04 , A61K31/4427 , A61K31/443 , A61K31/4439 , A61K31/485 , A61P25/28 , A61P29/00 , C07D205/04 , C07D401/12 , C07D401/14 , C07D405/14 , A61K31/44
Abstract: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula (I) which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.
-
-
-
-
-
-
-
-
-